MedTrace Logo

Viral Conjunctivitis Treatment Study

NCT03861728 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2021-12-29

Study results available
· View outcomes & findings →

Summary

The objective of this study is to determine the efficacy Avenova® (0.01% hypochlorous acid) in the treatment of viral conjunctivitis. The investigators hypothesize that patients treated with Avenova® will have a quicker resolution of their ocular signs and symptoms of Viral Conjunctivitis compared with artificial tears.

Conditions

  • Viral Conjunctivitis

Interventions

DEVICE

0.01% Hypochlorous acid

Randomized to treatment 0.01% Hypochlorous acid four times a day to the affected eye for 2 weeks. (Avenova is a FDA approved device)

OTHER

Placebo

Placebo to be used four times a day to the affected eye for 2 weeks

Sponsors & Collaborators

  • NovaBay Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • University of Miami

    lead OTHER

Principal Investigators

  • Wendy Lee, MD · Bascom Palmer Eye Institute, University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-14
Primary Completion
2020-02-08
Completion
2020-02-08
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03861728 on ClinicalTrials.gov